Receptor Tyrosine Kinase

What Receptor Tyrosine Kinase Means in Everyday Medical Language

Receptor tyrosine kinases, often called RTKs, are special proteins found on the surface of many cells in the body. You can think of them as tiny switches or antennas that receive signals from outside the cell. These signals tell the cell when to grow, divide, move, or survive. RTKs play a key role in normal cell functions and help cells communicate with each other.

Sometimes, the genes that make RTKs can have changes or mutations. These changes may cause the RTKs to become overactive or present in higher amounts than usual. When this happens, cells may grow uncontrollably, which can lead to cancer. Because of this, RTKs are important in understanding how some cancers develop and grow.

Why Receptor Tyrosine Kinases Matter in Cancer Care

RTKs are important in cancer care because they can drive the growth and spread of cancer cells. When RTKs are mutated or overactive, they send constant signals that encourage cancer cells to multiply and survive. This makes them a target for certain cancer treatments.

Some cancer drugs are designed to block these overactive RTKs. These drugs are called receptor tyrosine kinase inhibitors. By blocking the signals from RTKs, these treatments aim to slow down or stop cancer growth. For example, Herceptin is a well-known drug that targets the HER2 receptor, a type of RTK, in some breast cancers. Other experimental drugs, like ABT-869, block multiple RTKs and may also stop tumors from making new blood vessels, which tumors need to grow.

What Patients Might See or Hear About RTKs

Patients may come across the term receptor tyrosine kinase or RTK in different ways. It might appear in pathology reports, treatment plans, or discussions about targeted therapies. Sometimes, doctors mention RTKs when explaining how certain drugs work or why specific tests are done.

Because RTKs are involved in many types of cancer, the term can show up in reports about different cancers. You might also hear about drugs called receptor tyrosine kinase inhibitors, which are treatments that block these proteins. Examples include Herceptin for breast cancer or experimental drugs like ABT-869 in clinical trials.

Common Sources of Confusion and Related Terms

The term receptor tyrosine kinase can be confusing because it is sometimes shortened to RTK or used alongside names of specific proteins like HER2 or C-Kit. Different drugs may target different RTKs, and some drugs block several RTKs at once. For example, ABT-869 is called a multitargeted receptor tyrosine kinase inhibitor because it blocks multiple growth signals.

It’s also important to know that not all RTKs are the same, and not all cancers involve RTK changes. Seeing the term RTK does not automatically mean a cancer is aggressive or that a particular treatment will be used.

How to Use This Information and Next Steps

If you see receptor tyrosine kinase or RTK mentioned in your medical records or discussions, it’s a good idea to ask your care team what it means for your specific situation. Questions like “Does my cancer involve RTK changes?” or “Are there treatments that target RTKs for my cancer?” can help you understand your care better.

Remember, this information is educational and does not replace advice from your doctor. The role of RTKs and related treatments can vary widely depending on the type of cancer and individual factors. Your healthcare team can explain what RTKs mean in your test results or treatment plan and help you understand the best options for your care.